Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice

Kidney International

Volumn 70, Issue 3, 2006, Pages 507-514

  Zheng, F ^a,b   Zeng, Y J ^a   Plati, A R ^a   Elliot, S J ^a   Berho, M ^a   Potier, M ^a   Striker, L J ^a   Striker, G E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Advanced glycation end products; AGE inhibition; Angiotensin converting enzyme inhibitor; Diabetic nephropathy; Glomerular hypertrophy; Type II diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PYRIDOXAMINE; UNCLASSIFIED DRUG; VALSARTAN;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; ENZYME INHIBITION; FEMALE; GLOMERULONEPHRITIS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; COLLAGEN TYPE IV; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; MICE; MICE, INBRED C57BL; MICE, OBESE; PYRIDOXAMINE; TETRAZOLES; VALINE; VITAMIN B COMPLEX;

EID: 33746520563     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001578     Document Type: Article

References (35)

1. Pugh JA, Medina RA, Cornell JC, Basu S. NIDDM is the major cause of diabetic end-stage renal disease. More evidence from a tri-ethnic community. Diabetes 1995; 44: 1375-1380.
2. Engelgau MM, Geiss LS, Saaddine JB et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140: 945-950.
3. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866.
4. Lee HB, Yu MR, Yang Y et al. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003; 14: S241-S245.
5. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999; 257: 251-258.
6. Wendt T, Tanji N, Guo J et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003; 14: 1383-1395.
7. Vlassara H, Uribarri J. Glycoxidation and diabetic complications: modern lessons and a warning? Rev Endocr Metab Disord 2004; 5: 181-188.
8. Derubertis FR, Craven PA. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 1994; 43: 1-8.
9. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003; 25: 275-281.
10. Yang CW, Vlassara H, Peten EP et al. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994; 91: 9436-9440.
11. Kelly DJ, Gilbert RE, Cox AJ et al. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001; 12: 2098-2107.
12. Forbes JM, Cooper ME, Thallas V et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51: 3274-3282.
13. Forbes JM, Thallas V, Thomas MC et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003; 17: 1762-1764.
14. Nakamura S, Tachikawa T, Tobita K et al. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl) lysine accumulation in glomeruli of diabetic rats. Am J Kidney Dis 2003; 41: S68-S71.
15. Booth AA, Khalifah RG, Todd P, Hudson BG. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem 1997; 272: 5430-5437.
16. Degenhardt TP, Alderson NL, Arrington DD et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-950.
17. Alderson NL, Chachich ME, Frizzell N et al. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia 2004; 47: 1385-1395.
18. Zheng F, Cornacchia F, Schulman I et al. Development of albuminuria and glomerular lesions in normoglycemic B6 recipients of db/db mice bone marrow: the role of mesangial cell progenitors. Diabetes 2004; 53: 2420-2427.
19. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000; 36: 449-467.
20. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000; 77: S93-S98.
21. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000; 57: 1803-1817.
22. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
23. Metz TO, Alderson NL, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 2003; 419: 41-49.
24. Lee GH, Proenca R, Montez JM, Carroll KM et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996; 379: 632-635.
25. Chen H, Charlat O, Tartaglia LA et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84: 491-495.
26. Like AA, Chick WL. Studies in the diabetic mutant mouse. I. Light microscopy and radioautography of pancreatic islets. Diabetologia 1970; 6: 207-215.
27. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156: 286-289.
28. Sasaki M, Uehara S, Ohta H et al. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice. Life Sci 2004; 75: 869-880.
29. Duggan KA, Hodge G, Makarious MM, Charlesworth JA. Differential efficacy of perindopril and enalapril in experimental diabetic nephropathy. Clin Exp Pharmacol Physiol 1996; 23: 608-610.
30. Sato Y, Iwase M, Wakisaka M et al. Renoprotective effect of enalapril in uninephrectomized spontaneously hypertensive rats with neonatal streptozotocin-induced diabetes. Diabetes Res Clin Pract 1995; 29: 153-161.
31. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
32. Karl M, Potier M, Schulman IH et al. Autocrine activation of the local insulin-like growth factor I system is up-regulated by estrogen receptor (ER)-independent estrogen actions and accounts for decreased ER expression in type 2 diabetic mesangial cells. Endocrinology 2005; 146: 2889-2900.
33. Zheng F, Plati AR, Potier M et al. Resistance to glomerulosclerosis in B6 mice disappears after menopause. Am J Pathol 2003; 162: 1339-1348.
34. Mitsuhashi T, Vlassara H, Founds HW, Li YM. Standardizing the immunological measurement of advanced glycation endproducts using normal human serum. J Immunol Methods 1997; 207: 79-88.
35. Jacot TA, Striker GE, Stetler-Stevenson M, Striker LJ. Mesangial cells from transgenic mice with progressive glomerulosclerosis exhibit stable. phenotypic changes including undetectable MMP-9 and increased type IV collagen. Lab Invest 1996; 75: 791-799.